Calidi Biotherapeutics Sells 22.5M Nova Cell Shares For $6M; Nova Cell No Longer Subsidiary; Estimates It Will Realize $500K Per Year In General And Administrative Expense Reductions As A Result Of The Transaction

On October 27, 2025, Calidi Biotherapeutics, Inc. (the "Company") entered into that certain Stock Repurchase Agreement (the "SRA") and Material Purchase Agreement (the "MPA" and together with the SRA the "Agreements"), with its majority owned subsidiary, Nova Cell, Inc. ("Nova Cell"). Pursuant to the SRA, the Company sold and transferred 22,500,000 shares of Nova Cell common stock (the "Repurchased Shares"), which represents 75% of the equity interest in Nova Cell and 100% of the Company's ownership of Nova Cell, for a purchase price of $6,000,000 (the "Purchase Price"). The Purchase Price for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory note, net of specified offsets (including a $50,000 cash offset), resulting in an Indebtedness Cancellation Amount of $1,214,864, and (B) the balance, by Deferred Consideration of $4,785,136 payable after closing, as more fully described in the SRA. After the Deferred Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, payable quarterly within 30 days after each quarter-end. Following the closing, Nova Cell is no longer a subsidiary of the Company. The Company estimates it will realize $0.5 million per year in general and administrative expense reductions as a result of the transaction.

 

The MPA amends and supersedes in its entirety the parties' July 28, 2024, Intellectual Property Assignment Agreement, and, together with the Bill of Sale provides for the sale and transfer to Nova Cell of the purchased materials listed on Schedule 1, subject to stated limitations or applicable third-party rights. Nova Cell also assumed certain defined liabilities and agreed to a Prohibited Use covenant (including a prohibition on any uses relating to oncolytic viruses) pursuant to the MPA. The parties also executed a Bill of Sale to effectuate conveyance of the purchased materials under the MPA, subject to the MPA's terms. The Company will retain stocks of the cell lines listed as part of the Purchased Materials in Schedule 1 for its own use.

 

The foregoing summaries of the SRA and the MPA do not purport to be complete and are qualified in their entirety by reference to the SRA and the copies of which are filed as Exhibits 10.1, and 10.2, respectively, to this Current Report on Form 8-K, and incorporated herein by reference.